Recently, at the 2025 American Society of Hepatology Annual Meeting, the clinical research team of the Liver Disease Center of Southern Hospital reported on the latest phase II clinical research of HT-101+HT-102 combination therapy in the functional treatment of chronic hepatitis B. HT-101 is a small interfering RNA conjugated to GalNAc that targets to silence hepatitis B virus transcripts in hepatocytes and inhibits the production of HBsAg at the source; HT-102 is an all-human monoclonal antibody that is used to quickly remove HBsAg already generated from blood. The two work together to form a “suppression+elimination” closed-loop treatment model. In existing treatments, although nucleoside analogs can effectively inhibit virus replication, it is difficult to achieve continuous removal of HBsAg after discontinuation of the drug, and patients usually need to take medication for a long time or even for life. The results of this study showed significant efficacy and was dose-dependent: in patients with baseline HBsAg >1000 IU/ml, 100% HBsAg was reduced to <10 IU/ml after 20 weeks of treatment; in patients with baseline HBsAg <1000 IU/ml, the hepatitis B surface antigen clearance rate reached 100% within 20 weeks.

Zhitongcaijing · 11/20/2025 04:17
Recently, at the 2025 American Society of Hepatology Annual Meeting, the clinical research team of the Liver Disease Center of Southern Hospital reported on the latest phase II clinical research of HT-101+HT-102 combination therapy in the functional treatment of chronic hepatitis B. HT-101 is a small interfering RNA conjugated to GalNAc that targets to silence hepatitis B virus transcripts in hepatocytes and inhibits the production of HBsAg at the source; HT-102 is an all-human monoclonal antibody that is used to quickly remove HBsAg already generated from blood. The two work together to form a “suppression+elimination” closed-loop treatment model. In existing treatments, although nucleoside analogs can effectively inhibit virus replication, it is difficult to achieve continuous removal of HBsAg after discontinuation of the drug, and patients usually need to take medication for a long time or even for life. The results of this study showed significant efficacy and was dose-dependent: in patients with baseline HBsAg >1000 IU/ml, 100% HBsAg was reduced to <10 IU/ml after 20 weeks of treatment; in patients with baseline HBsAg <1000 IU/ml, the hepatitis B surface antigen clearance rate reached 100% within 20 weeks.